Gabrielle Lakusta

glakusta@resourceinvestingnews.com

Articles

IMFINZI (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer

AstraZeneca (NYSE:AZN) and MedImmune, its global biologics research and development arm, today announced positive overall survival (OS) results for the...

May 25th, 2018

Alexion Offer for Wilson Therapeutics Accepted

Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been...

May 25th, 2018

Oncolytics Biotech Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN with Keytruda, Velcade and Dexamethasone

Oncolytics Biotech (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a collaboration with...

May 25th, 2018

Microbot Medical Closes Acquisition of Novel Technology from CardioSert

Microbot Medical (NASDAQ CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today...

May 25th, 2018

Amarin Announces Patent Litigation Settlement Agreement with Teva

Amarin (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today a settlement...

May 25th, 2018

BioCryst’s BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema

BioCryst Pharmaceuticals (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the...

May 25th, 2018

Recro Pharma’s Shares Plunges Following FDA Letter

Following the announcement on Thursday, shares of Recro Pharma dropped in dramatic fashion by nearly 55 percent to close the...

May 24th, 2018

Medicenna Receives Amendment to Revamp Clinical Trial

The Investing News Network had the opportunity to speak with Medicenna CEO Fahar Merchant at the Bloom Burton & Co....

May 24th, 2018

Chembio Diagnostics Announces Agreement with Bio-Manguinhos to Commercialize Point-of-Care Tests for Dengue, Zika and Chikungunya in Brazil

Chembio Diagnostics (Nasdaq:CEMI), a leader in point-of-care (“POC”) diagnostic tests for infectious diseases, today announced the signing of a long-term...

May 24th, 2018

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

Merus (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been...

May 24th, 2018